Trust Point’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$615K Buy
4,129
+624
+18% +$87.6K 0.05% 217
2026
Q2
$443K Buy
3,505
+342
+11% +$45.1K 0.04% 248
2026
Q1
$441K Buy
3,163
+49
+2% +$6.86K 0.04% 285
2025
Q4
$382K Buy
3,114
+68
+2% +$8.26K 0.03% 302
2025
Q3
$338K Sell
3,046
-1,485
-33% -$169K 0.03% 334
2025
Q2
$502K Buy
4,531
+1,495
+49% +$159K 0.05% 188
2025
Q1
$340K Sell
3,036
-1,177
-28% -$121K 0.03% 309
2024
Q4
$389K Buy
4,213
+169
+4% +$15.2K 0.03% 352
2024
Q3
$339K Buy
4,044
+565
+16% +$43.1K 0.03% 361
2024
Q2
$239K Sell
3,479
-339
-9% -$22.6K 0.02% 438
2024
Q1
$280K Sell
3,818
-683
-15% -$52.5K 0.02% 423
2023
Q4
$365K Buy
+4,501
New +$350K 0.03% 347

Other funds holding GILD

Trust Point's GILD Position: Q3 2026 in Review

Trust Point increased its Gilead Sciences (GILD) stake by 18% in Q3 2026, buying an estimated $87.6K and bringing the position to 4,129 shares worth $615K. The position accounts for 0.05% of the portfolio, ranked #217.

Trust Point first reported a position in GILD in Q4 2023 and has held it in 12 quarters since. 2,060 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Trust Point held 4,129 shares of Gilead Sciences worth $615K as of Q3 2026.
  • Trust Point bought 624 Gilead Sciences shares in Q3 2026, an estimated $87.6K.
  • Gilead Sciences made up 0.05% of Trust Point's portfolio in Q3 2026, its #217 holding.
  • Trust Point first reported a position in Gilead Sciences in Q4 2023 and has held it in 12 quarters since.
  • 2,060 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.